3 Hidden-Gem Small-Caps Quietly Winning While AI Steals the Show

Fundstrat flagged it on YouTube this week: healthcare just hit all-time highs, energy already ran nearly 40% earlier this year, and tech is taking a breather. That's the classic sector rotation playbook, and the smart move right now isn't chasing what everyone already owns. It's finding the weird little companies doing interesting things in corners of the market that financial Twitter hasn't discovered yet. Here are three of them.

$PRVA (Privia Health Group) doesn't sound like a barn-burner, but hear it out. Privia is a physician enablement platform that helps independent doctors run their practices using value-based care infrastructure, basically the picks-and-shovels play for the part of healthcare that isn't a hospital. Market cap sits comfortably under $2 billion. It's under the radar because it operates in the unsexy administrative layer of medicine, not drug discovery or flashy biotech. The catalyst is simple: as healthcare hits all-time highs and investors rotate into the sector, physician-facing platforms that improve margins for medical groups become very interesting acquisition targets for larger health systems or insurers looking to own the patient relationship.

$FWRG (Front Wave Restaurant Group) is the kind of name that makes you do a double take. This is a fast-casual franchise operator focused on regional markets across the Sun Belt, under $1 billion in market cap. It's obscure because it doesn't have the Chipotle brand recognition or the Shake Shack social media halo. But with Starbucks reportedly passing on a Chipotle acquisition per this week's Bloomberg quiz segment, it signals that even major QSR dealmaking is in flux, and smaller regional operators with proven unit economics can get scooped up fast. Watch same-store sales comps in Q3 earnings as the near-term catalyst.

$LQDA (Liquidia Corporation) is a pulmonary arterial hypertension drug developer that most people have never heard of, even though it has an FDA-approved product on the market and an ongoing patent battle with United Therapeutics that could unlock a massive addressable market. Market cap is around $1.5 billion. The bear case is real: litigation risk is existential if the patents don't hold. The bull case is equally real: if Liquidia wins or settles favorably, this becomes a multi-bagger from current levels. It's the kind of binary setup that small-cap specialists live for.